Matinas BioPharma Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $10.63M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | – | $-0.02 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | $-0.03 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 8, 2023 | During market hours | – | $-0.03 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 9, 2023 | During market hours | – | $-0.03 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 10, 2023 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 15, 2023 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 2, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 11, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 8, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 8, 2021 | Before market open | – | – | – |
Press releases
Announcements Matinas BioPharma filed with the SEC
BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Listing notice · Other events · EX-99.1 to Form 8-K
BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Listing notice · Other events · EX-99.1 to Form 8-K
BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
Executive or director change · Other events · EX-99.1 to Form 8-K
BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Exit or restructuring costs · Material impairment · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
BioPharma Announces Registered Direct Offering of $10 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Reports 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Regains Compliance with NYSE American Continued Listing Standards
Other events · EX-99.1 to Form 8-K
BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
BioPharma Announces Notification of NYSE American Continued Listing Deficiency
Listing notice · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BioPharma Reports 2022 Financial Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
BioPharma Provides Business Update and 2023 Strategic Outlook
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
end of any year is a good time to reflect upon our accomplishments as a company and to recognize some of the things that we can work
Regulation FD disclosure · EX-99.1 to Form 8-K
BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
BioPharma Announces Positive Interim Data from the Phase 2
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K